Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH5201+ durvalumab+ standard chemotherapy · 1 trial · 1 indication
Number of patients with pathological Complete Response (pCR)
Number of patients with adverse events (AEs) and serious adverse events (SAEs).
| Arm | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | EXPERIMENTAL | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
| Name | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | DRUG | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
Inclusion criteria Patients are eligible to be included in the study only if all of the following criteria apply: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. 2. Provis...
Top 20 of 84 competitors
IPH5201 + durvalumab + standard chemotherapy is an investigational combination being studied for the treatment of Non Small Cell Lung Cancer (NSCLC). It is currently in Phase 2 clinical development, specifically for patients with resectable non-small cell lung cancer, as part of the MATISSE trial.
IPH5201 + durvalumab + standard chemotherapy is being developed by Innate Pharma S.A., a biopharmaceutical company. The company's ticker symbol is IPHA. The combination is being evaluated in a Phase 2 clinical trial for Non Small Cell Lung Cancer.
IPH5201 + durvalumab + standard chemotherapy is in Phase 2 clinical development. It is an investigational combination therapy, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for Non Small Cell Lung Cancer.
IPH5201 + durvalumab + standard chemotherapy is being studied in the MATISSE trial, registered as NCT05742607. This Phase 2 trial is recruiting patients with resectable Non Small Cell Lung Cancer and has an enrollment target of 70 participants across the United States, France, Greece, Hungary, and Poland.
Yes, IPH5201 + durvalumab + standard chemotherapy is also known as IPH5201 + durvalumab + standard chemotherapy. These names refer to the same investigational combination therapy being developed by Innate Pharma for Non Small Cell Lung Cancer.